SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

SPARC shines on receiving CRL from USFDA for Latanoprost NDA

02 Dec 2014 Evaluate

Sun Pharma Advanced Research Company (SPARC) is currently trading at Rs. 201.60, up by 20.05 points or 11.04% from its previous closing of Rs. 181.55 on the BSE.

The scrip opened at Rs. 190.00 and has touched a high and low of Rs. 208.50 and Rs. 190.00 respectively. So far 1111598 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 218.60 on 09-Sep-2014 and a 52 week low of Rs. 144.10 on 31-Mar-2014.

Last one week high and low of the scrip stood at Rs. 188.20 and Rs. 180.00 respectively. The current market cap of the company is Rs. 4726.99 crore.

The promoters holding in the company stood at 67.13% while Institutions and Non-Institutions held 6.03% and 26.84% respectively.

U.S. Food and Drug Administration (FDA) has issued a Complete Response letter (CRL) to Sun Pharma Advanced Research Company’s (SPARC’s) New Drug Application (NDA) for Latanoprost BAK-free eyedrops.

While the FDA did not seek any additional information for supporting clinical data, it sought additional information on certain labeling and other deficiencies for processing the NDA.

SPARC believes that this additional information request from the FDA can be addressed on priority. SPARC is an international pharmaceutical company engaged in research and development of drugs and delivery systems.

 

Sun Pharma Adv. Res Share Price

147.90 -4.25 (-2.79%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Syngene Internation. 435.70
Indegene 486.80
CMS Info Systems 318.00
JITF Infralogistics 338.00
Sagility 42.95
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×